

## Giving you practical guidance on managing respiratory diseases

The following document provides you with a sample of an Opinion Sheet from the PCRS-UK. The 'Routine use of oxygen in Primary Care' Opinion Sheet can be found on the following page.

The Primary Care Respiratory Society UK provides a range of concise, easy-to-follow summary publications, called Opinion Sheets, for you and your colleagues. Each is written by expert healthcare professionals and is aimed at providing practical guidance on all aspects of the primary care management of respiratory disease.

These Opinion Sheets offer a wealth of respiratory care information and address many key topics and concerns. For instance, you'll discover advice on a wide range of issues on the management of asthma and COPD, as well as information on those conditions we see less frequently, such as lung cancer and interstitial lung disease. Opinion Sheets are freely available for members of the PCRS-UK to download. They're designed to be used in everyday practice and as a platform for practice training and professional development.

So, with more than 40 Opinion Sheets to choose from, you're more than likely to find the relevant information you need in a concise and easy-to-read format. New Opinion Sheets are being added regularly. Here is a list of the Opinion Sheets currently available to members:

**Allergy** – Allergic Rhinitis • Allergic Rhinitis and Asthma • Allergy Testing in Primary Care • The role of Anti-Ig E Therapy in the Treatment of Severe Allergic Asthma • Rhinosinusitis.


**Asthma** – High Risk Asthma • Asthma – Special Situations • Asthma Review • Diagnosis of Asthma in Adults • Diagnosis of Asthma in Children • Inhaler Devices • Management of Asthma in Children • National Institute for Health and Clinical Excellence (NICE) Guidelines for Inhaled Steroids for the Treatment of Chronic Asthma • Personal Asthma Action Plans • The role of ICS and LABA, alone and in combination, in the management of Asthma.

**COPD** – Screening and Case Finding in COPD • Diagnosis of COPD • COPD Review • Home Oxygen Therapy • Management of Exacerbations of Chronic Obstructive Pulmonary Disease in Primary

Care • Management of Stable Chronic Obstructive Pulmonary Disease in Primary Care • Mucolytic Therapy • Palliative Care for people with COPD • Pulmonary Rehabilitation • Routine use of Oxygen in Primary Care • Self Management of COPD in Primary Care • Self Management and Self Care • Smoking Cessation • Spirometry • The use of LABA and ICS in the Management of COPD • Hospital at Home • The Use of Pulse Oximetry in Primary Care • COPD Review.

**Other** – Bronchiectasis • Differential Diagnosis of the Breathless Patient • Management of Occupational Lung Disease in Primary Care • Management of Cough in Primary Care • Sleep Apnoea • Lung Cancer • Pneumonia • What every GP should know about rarer Lung Conditions.

A range of other resources have been created by the PCRS-UK to help healthcare professionals deliver high quality respiratory services. They include: summary guidance information, nursing tools such as protocols, clinic checklists and PGDs. We also offer a range of resources aimed at professional development, such as slide kits and online case studies to assist with personal reflection.



# Opinion

## Routine use of oxygen in Primary care

### Principles for administering oxygen

Oxygen is a medication. It is prescribed and administered for the treatment of hypoxia both in emergency situations, and in more chronic conditions such as COPD and lung fibrosis. More controversially, it is sometimes used in conditions such as cluster headaches where the evidence is weaker.

Whilst there is good evidence of benefit when oxygen is given to hypoxic patients, there is no evidence that its use for breathlessness without hypoxia is anything more than an expensive placebo.<sup>1</sup> To address the exponential rise in costs for oxygen treatment, current recommendations therefore advocate the use of target saturations measured with pulse oximetry to ensure that those requiring oxygen receive it and that those that do not are supported to manage their symptoms in other ways.<sup>2</sup>

### Pulse oximetry

Pulse oximetry should be available in all settings where emergency oxygen is used and to identify people with chronic conditions who would benefit from further assessment.<sup>3</sup> Oxygen saturations of between 94–98% are considered normal. Visual observation of cyanosis is unreliable and oxygen saturations measurements are essential.<sup>3</sup>

### Emergency situations

In an emergency, such as acute severe or life threatening asthma, where oxygen saturations are  $\leq 92\%$ , oxygen should always be administered using high flow oxygen (40–60%) via a high flow mask. (i.e. Hudson mask) Target saturations of between 94–98% are recommended for acutely ill patients although 88–92% is sufficient for those at risk of hypercapnic respiratory failure.<sup>4</sup>

When administering nebulised  $\beta_2$ -agonists with oxygen for acute asthma the flow rate required is 6 litres/minute, therefore a high flow regulator must be fitted to the oxygen cylinder.<sup>5</sup>

### Chronic conditions

For chronic respiratory conditions people with oxygen saturations  $< 92\%$  breathing room air, should be considered for a formal oxygen assessment with referral made to the local home oxygen assessment service.

It is worth noting that saturation level of  $< 90\%$  correlate poorly with arterial blood gas oxygen levels.<sup>6</sup>

For some chronic conditions, such as emphysema, the changes are gradual and it is important to recognise other signs of hypoxaemia such as reduced exercise capacity, cardiac arrhythmias, fatigue and confusion.<sup>7</sup> The only disease area where there is a proven survival benefit from the use of Long Term Oxygen Therapy (LTOT) is in patients with severe COPD and chronic resting arterial hypoxemia proven by arterial blood gas assessments.<sup>8,9</sup>

### Assessment and oxygen provision

#### Long Term Oxygen Therapy (LTOT)

LTOT is indicated for the management of confirmed chronic hypoxaemia defined as a resting arterial blood gas oxygen level ( $\text{PaO}_2$ ) at or below 7.3 Kilo Pascals (kPa) with oxygen saturations of  $< 90\%$ . Evidence supports LTOT being administered for at least 15 hours a day: and should include night time use as arterial hypoxaemia worsens during sleep.<sup>8,9</sup>

- Following an acute episode, a period of recovery is required before a formal LTOT assessment takes place. After a period of clinical stability of at least five weeks, two separate assessments are made two weeks apart. Sometimes oxygen may be prescribed temporarily whilst the patient recovers after a hospital admission, but primary care clinicians need to be aware that this should not be continued unless the formal assessments suggest it is appropriate.
- The assessment includes measuring acid base status, carbon dioxide and oxygen levels in arterial or ear lobe capillary blood gas whilst at rest. The initial test is performed breathing room air, and is then repeated following the introduction of supplementary oxygen. Oxygen tension on treatment should be raised to above 8kPa.
- If LTOT is ordered the person should be reviewed on a regular basis by a respiratory specialist.
- LTOT is provided through a concentrator usually via nasal prongs. Depending on the results of the assessment the flow rate is usually between 2–4 litres.<sup>6</sup>
- For those people with COPD or known

respiratory failure following formal oxygen assessment lower saturation levels may be accepted.

- Smokers are strongly advised to stop smoking, though failure to quit is not an absolute contra-indication to provision of LTOT.

LTOT can be prescribed for people with chronic hypoxaemia and a clinically stable  $\text{PaO}_2$  between 7.3kPa and 8kPa with the presence of either of the following:

- Secondary polycythaemia
- Pulmonary hypertension confirmed by echocardiogram

#### Ambulatory Oxygen (AO)

AO assessment is for those people who show arterial oxygen de-saturation on exercise, (defined as a fall in  $\text{SpO}_2$  of 4% to below 90%) AND have the motivation to use AO. Formal assessment should be undertaken, including a walk tests initially on air and then on oxygen demonstrating an improvement in  $\text{SpO}_2$  and an improvement in exercise capacity.

AO may be used for people

- on LTOT who are active outside the home
- People who desaturate on exercise

Ambulatory oxygen aims to:

- Enable people to leave their home
- Improve quality of life
- Increase everyday activities
- Improve exercise capacity
- Reduce breathlessness
- Enhance rehabilitation
- Increase the number of hours of LTOT use

Portable systems or liquid oxygen (for those people with a high usage) are available.<sup>6</sup>

#### Intermittent Oxygen therapy also known as Short Burst (SBOT)

Traditionally, short burst oxygen has been prescribed to relieve periods of breathlessness. To date, there is no evidence to support the use of oxygen in this manner. Causes of breathlessness should be excluded and if  $\text{SaO}_2 < 92\%$ , and LTOT assessment should be considered.

Oxygen is often administered for palliation of breathlessness at the end of life care, but evidence suggests that, unless the patient is hypoxic, any moving air on the face (an open window, a hand-held fan) may provide similar subjective relief.<sup>10</sup>

## How to prescribe

Re-procurement of home oxygen service contracts are being established in each region. The service includes:

- A new patient Home Oxygen Consent Form (HOCF). With the first order for oxygen, the patient is required to sign a HOCF allowing information to be shared with the contractor.
- A new Home Oxygen Order Form (HOOF). The clinician completing the HOOF will specify the exact equipment the patient requires
  - Part A for non specialist services
  - Part B for post assessment specialist Oxygen assessment

### Part A. To be used for non specialist ordering

Home Oxygen Order Form (HOOF)  
Part A (Before Oxygen Assessment - Non-Specialist or Temporary Order)

**1. Patient Details**

1.1 NHS Number\* 1.2 Permanent address\* 1.3 Tel no. 1.4 Title

1.3 Surname\* 1.5 First name\* 1.6 Gender  Male  Female 1.8 Postcode\* 1.9 Tel no. 1.10 Mobile no.

**2. Carer Details (if applicable)**

2.1 Name 2.2 Tel no. 2.3 Mobile no.

**3. Clinical Details**

3.1 Clinical Code(s) 4.1 Main Practice name\* 4.2 Practice address\* 4.3 Postcode\* 4.4 Tel no.

3.2 Patient on NIV/CPAP  Yes  No 4.3 Practice address\* 4.3 Postcode\* 4.4 Tel no.

3.2 Paediatric Order  Yes  No

**5. Assessment Service (Hospital or Clinical Service)**

5.1 Hospital or Clinic Name 6.1 Name 6.2 Tel no. 6.3 Fax no. 6.4 Reference date / /

5.2 Address 6.2 Tel no. 6.3 Fax no. 6.4 Reference date / /

5.3 Postcode 5.4 Tel no.

**7. Order\***

7.1 Type 7.2 Hours / Day 7.3 Start Date 7.4 End Date

**8. Equipment\***

8.1 Type 8.2 Flow Rate (litres per minute) 8.3 Concentration (%) 8.4 Other details

**9. Consumables\***

9.1 Type 9.2 Quantity 9.3 Other details

**10. Delivery Details\***

10.1 Standard (3 Business Days)  10.2 Urgent (1-2 Days)  10.3 Urgent (4 Hours)

**11. Additional Patient Information**

11.1 Other conditions 11.2 Other details

**12. Clinical Contact (if applicable)**

12.1 Name 12.2 Tel no. 12.3 Mobile no.

**13. Declaration\***

I declare that the information given on this form for NHS treatment is correct and complete. I understand that if I knowingly provide false information, I may be liable for prosecution or civil proceedings. I confirm that I am the registered healthcare professional responsible for the information provided. I have explained to the patient his need and signed the Home Oxygen Consent Form.

Name: \_\_\_\_\_ Profession: \_\_\_\_\_  
Signature: \_\_\_\_\_ Date: \_\_\_\_\_ Referred for assessment:  Yes  No

Print back No. or NHS email address for confirmation / correction:

**14. Clinical Code**

CODE	Condition	CODE	Condition
1	Chronic obstructive pulmonary disease (COPD)	12	Nocturnal hypoxaemia
2	Pulmonary vascular disease	13	Obstructive sleep apnoea syndrome
3	Severe chronic asthma	14	Chronic heart failure
4	Idiopathic lung disease	15	Paediatric respiratory lung disease
5	Cystic fibrosis	16	Chronic neonatal lung disease
6	Bronchiectasis (not cystic fibrosis)	17	Paediatric cardiac disease
7	Pulmonary malignancy	18	Cluster headache
8	Pulmonary sarcoid	19	Other primary respiratory disorder
9	Non-pulmonary palliative care	20	Other
10	Chest wall disease	21	Not known
11	Neuromuscular disease		

## What is different?

Part 5 - New section for recording assessment centre details

Part 7 - PART A can only order basic domiciliary oxygen modalities

Part 11- Can be used if standard ambulatory is required

AM or PM delivery can be requested

There is a rental fee for each piece of equipment and activity based charge for installation, risk assessments, replenishments and servicing. Therefore good clinical assessment and correct ordering is essential. Ideally patients should be referred to specialist home oxygen assessment services who are able to assess the patient suitability for a range of modalities for oxygen provision.<sup>6</sup>

The supplier will contact the patient to carry out a telephone safety assessment this will be followed up with a field based risk assessment. The contractor will deliver the

oxygen systems directly to the patient; install the system according to the oxygen requested on the HOOF, and give instruction on safety and how to use the equipment.

The supplier will arrange a 2 week phone call to all patients following installation and alert the Fire Brigades of new a installation within 2 days.

For any subsequent changes to oxygen treatment a 're-HOOF' is required. Copies of the HOOF should be available in the GP records, the Home Oxygen Service and the relevant PCT.

## Education

The health professional should provide education and written information for the patient and carer. This should cover diagnosis and management, the reason and frequency of oxygen use. It should explain how the flow rate has been set following assessment and the length of time oxygen should be used and the reasons for follow up assessments.

The supplier will provide written information on the oxygen equipment. The engineer will discuss home servicing, electricity reimbursement, when to use the back up oxygen cylinder and emergency breakdown contact numbers.

## Risks

These are mostly associated with open flames, smoking (especially the lighting of cigarettes), heat sources ie candles, gas and the use of combustible/flammable product such as creams containing petroleum. Patients should also be instructed to turn the oxygen supply off when not in use.

## Travel

For travel in the UK there is no requirement for a holiday HOOF – unless there is a change in requirements. The patient or carer should inform the supplier of the dates of the holiday and the holiday address (this must be within England & Wales). The Supplier will forward the original HOOF to the supplier of the region being visited by the patient within four hours of receipt. This will be completed within a 3 day service level agreement – please advise the patient to give as much notice as possible. Holiday weekend installations are available.

People with a resting oxygen saturation of less than 94% may be hypoxic if they travel by air and should be referred for formal flight oxygen assessment. Information about travelling with oxygen is available from the web-site of the European Lung Foundation ([www.european-lungfoundation.org](http://www.european-lungfoundation.org))

## Assessing the effectiveness of oxygen therapy

All patients using LTOT or ambulatory oxygen should be routinely monitored as rec-

ommended in the BTS guidelines.<sup>2</sup> Monitoring oxygen saturations using a pulse oximeter is a useful guide of the state of oxygenation, remembering that caution should be used in ensuring COPD patients are not over-oxygenated. Arterial blood gas analysis is the gold standard in measuring the results of oxygen therapy and provides accurate information on the pH, PaCO<sub>2</sub> and PaO<sub>2</sub>. The clinical response of the patient in terms of physical comfort, sleep, and mobility, must also be evaluated on a regular basis.

## Oxygen sensitivity

Patients who are known to retain CO<sub>2</sub> or have type 2 respiratory failure should be given an oxygen alert card to ensure that they are given controlled oxygen rather than high flow in an acute situation.<sup>2</sup>

## What materials / resources are available?

A number of professional resources are available as listed in the references. An NHS website for public and professionals is available [www.homeoxygen.nhs.uk](http://www.homeoxygen.nhs.uk). In addition, information for people using oxygen will be provided by the company and further patient information can be sourced at the British Lung Foundation website. [www.lunguk.org](http://www.lunguk.org)

## References

1. Moore RP, Berlowitz DJ, Denehy L, *et al.* A randomised trial of domiciliary, ambulatory oxygen in patients with COPD and dyspnoea but without resting hypoxaemia. *Thorax* 2011;**66**:32-7.
2. British Thoracic Society; Working Group on Home Oxygen Services. *Clinical Component for the home oxygen service in England and Wales*. BTS: 2006. (Available from <http://www.brit-thoracic.org.uk>)
3. Holmes S, Peffer SJ. *Pulse oximetry in Primary Care*. Opinion sheet 28. PCRS-UK: 2009
4. British Thoracic Society Guideline for Emergency Oxygen Use in Adult Patients. *Thorax* 2008; **63**(Suppl6): vi1-vi68 (Available from <http://www.brit-thoracic.org.uk>)
5. Levy ML, Thomas M, Small IR, Pearce L, Pinnock H, Stephenson P. Summary of the 2008 BTS/SIGN British Guidelines on the Management of Asthma. *Prim Care Respir J* 2009;**18**(suppl1):S1-S16. <http://dx.doi.org/10.3132/pcrj.2008.00067>
6. Pearce L. *Home oxygen therapy*. Opinion sheet no 8. Ed2. PCRS-UK 2011
7. National Institute for Health and Clinical Excellence. *Management of chronic obstructive pulmonary disease in adults in primary and secondary care*. London: National Clinical Guideline Centre 2010. (Available from <http://www.nice.ac.uk>)
8. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. *Ann Intern Med* 1980;**93**:391-8.
9. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. *Lancet* 1981;**1**:681-6.
10. Booth S, Anderson H, Swannick M, *et al.* The use of oxygen in the palliation of breathlessness. A report of the expert working group of the scientific committee of the association of palliative medicine. *Respir Med* 2004;**98**:66-77.

Date of Preparation: March 2011 Revised: November 2011 Author: Linda Pearce, Bury St Edmunds, Suffolk

Conflict of interest: None Editor: Hilary Pinnock, University of Edinburgh

Address for Correspondence: PCRS-UK, Smithy House, Waterbeck, Lockerbie, DG11 3EY, UK Telephone: +44 (0)121 767 1928 Facsimile: +44 (0)121 336 1914

Websites: <http://www.pcrs-uk.org>, <http://www.thepcrj.com> Email: [info@pcrs-uk.org](mailto:info@pcrs-uk.org)

# Want to keep up-to-speed with all the latest developments in respiratory primary care?



These Opinion Sheets are just a small part of what the PCRS-UK can do for you, your colleagues and your practice team. Join the PCRS-UK today and you can join the people already making a difference in respiratory primary care.

Whether you're a primary care nurse searching for tried and tested protocols, a GP looking for guidance on COPD diagnosis and management, or a respiratory specialist interested in the latest research, it makes sense to become a member of the Primary Care Respiratory Society UK.

As a member, you'll have unlimited access to a wealth of specialist respiratory care information, expertise and resources and practical everyday tools.

## Join the PCRS-UK today and get all these benefits

- ✓ **Make life easier.** Become a member of the PCRS-UK and discover a wealth of credible respiratory care information all in one place
- ✓ **Keep pace with developments.** From COPD guideline changes to managing asthma, there's a best practice resource waiting for you
- ✓ **Get help with professional development.** Save time. It's ready to download and you can even share it with your practice staff
- ✓ **Benefit from expert advice.** From managing allergic rhinitis to using spirometry, you'll find even more easy-to-follow Opinion Sheets online
- ✓ **Read regular e-alerts.** Get the latest respiratory information, news and updates, direct to your inbox.

## Choose your membership options

### Practice Membership

Join the PCRS-UK Practice Membership scheme today. No matter how big your team, one subscription fee means everyone in your practice can access the latest resources, written by experts who understand both primary and respiratory care.



### Premium Membership

Designed for those with a specific interest in respiratory disease. Offers all the benefits of regular membership PLUS discounts at events, access to the respiratory leader programme and a free hard copy of quarterly PCRJ.



### E-connect Membership

If you don't work in a practice, or just want to join as an individual, E-connect membership offers all the benefits of practice membership as an affordable alternative.



Join today and get the support of the UK's leading respiratory primary care experts

visit [www.pcrs-uk.org/join](http://www.pcrs-uk.org/join) or call 0121 767 1928

Date of preparation: 29/06/2011

The Primary Care Respiratory Society, formerly known as the General Practice Airways Group, is a registered charity (Charity No: 1098117) and a company limited by guarantee registered in England (Company No: 4298947) VAT Registration Number: 866 1543 09

Registered offices: 2 Wellington Place, Leeds, LS1 4AP

Address for correspondence: PCRS-UK, Smithy House, Waterbeck, Lockerbie, DG11 3EY

Telephone: +44 (0)121 767 1928 Facsimile: +44 (0) 121 336 1914 Email: [info@pcrs-uk.org](mailto:info@pcrs-uk.org) Website: <http://www.pcrs-uk.org>

The Primary Care Respiratory Society UK is grateful to its corporate supporters including Allen & Hanburys (the respiratory division of GlaxoSmithKline), Almirall Ltd, AstraZeneca UK Ltd, Boehringer Ingelheim Ltd / Pfizer Ltd, Chiesi Ltd, Napp Pharmaceuticals, Novartis UK and Orion Pharma (UK) Ltd, TEVA UK Ltd for their financial support which supports the core activities of the Charity and allows the PCRS-UK to make its services either freely available or at greatly reduced rates to its members.